ASH 2025 summary video interviews
Latest news
The largest haematology meeting in the world has just finished. The American Society of Hematology (ASH) Annual Congress took place in Orlando, Florida, US, where the latest research in blood diseases was presented. Myeloma Patients Europe (MPE) interviewed key experts to learn more about the most relevant studies and abstracts in myeloma and AL amyloidosis.
Watch these interviews to learn what the most important updates were in myeloma and AL amyloidosis and why these results matter for people living with these conditions. Click on the thumbnails to watch.
Dr. Charlotte Pawlyn – Majestec-3
Dr. Charlotte Pawlyn from The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK, explains the main results of MajesTEC-3, one of the most important myeloma studies. This trial compared the combination of teclistamab and daratumumab (Tec-Dara) versus daratumumab with either pomalidomide or bortezomib and dexamethasone in patients who had received one to three previous lines of treatment. The Tec-Dara combination showed unprecedented benefits when used earlier in the myeloma pathway.
Dr. Phoebe Joy Ho – inMMyCAR
Dr. Phoebe Joy Ho from the Royal Prince Alfred Hospital and the University of Sydney, Australia, explains the results of inMMyCAR. This first-in-human study of KLN1010, a novel “in vivo” CAR T-cell therapy targeting BCMA, showed very good responses in four treated patients with no serious instances of cytokine release syndrome (CRS) or neurotoxicity (ICANs).
Dr. Bruno Paiva – GEM-CESAR
Dr. Bruno Paiva, Clínica Universidad de Navarra, Madrid, Spain, explains the main results of the GEM-CESAR clinical trial presented at ASH 2025. This a study assessing early rescue treatment with daratumumab, pomalidomide and dexamethasone (DPd) in people with high-risk smoldering myeloma.
Dr. Shambavi Richard – DURGA-1
Dr. Shambavi Richard, Icahn School of Medicine at Mount Sinai, New York, United States, explains the main results of the DURGA-1 trial evaluating AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy using FasTCAR technology for rapid manufacturing. Early data showed promise for this dual-target approach in relapsed/refractory multiple myeloma patients.
Dr. Xavier Leleu – LINKER-MM4
Dr. Xavier Leleu, Centre Hospitalier Universitaire de Poitiers, France, explains the main results of the LINKER-MM4 clinical trial which evaluates safety and efficacy of linvoseltamab as a simplified monotherapy in first-line regimen in newly diagnosed myeloma patients.
Dr. Charlotte Pawlyn – UK MRA FiTNESS trial
Dr. Charlotte Pawlyn, from The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK, explains the main results of the MRA FiTNESS trial, which aims to understand whether the International Myeloma Working Group (IMWG) frailty score can be used to tailor treatment according to a myeloma patient’s level of fitness.
Dr. Phoebe Joy Ho – CAMMA-3
Dr. Phoebe Joy Ho, Royal Prince Alfred Hospital and University of Sydney, Australia, explains the first results from the phase Ib CAMMA-3 study, in which subcutaneous cevostamab shows manageable safety and meaningful clinical activity in relapsed/refractory myeloma (RRMM).
Dr. Dominik Dytfeld – COBRA trial
Dr. Dominik Dytfeld, Poznan University of Medical Sciences, Poland, lead author of the COBRA trial, explains this study evaluating carfilzomib, lenalidomide and dexamethasone (KRd) versus bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma (NDMM).
Dr. Bruno Pavia – NoMoreMGUS
Dr. Bruno Paiva, Clínica Universidad de Navarra, Madrid, Spain, explains the main results of the NoMore MGUS clinical trials, one of the largest MGUS (Monoclonal Gammopathy of Undetermined Significance) data collection trials in the world.
Dr. Salomon Manier – IFM2021-01 trial
Dr.Salomon Manier, University of Lille, France, talks through this teclestameb trial. This study shows that an “all-antibody–based” doublet regimen of teclistamab and daratumumab is highly effective and well-tolerated in elderly newly diagnosed myeloma patients.
Dr. Paolo Milani – AL amyloidosis highlights
Dr. Paolo Milani, University of Pavia, Italy, explains for MPE the most important AL amyloidosis updates presented at ASH 2025, as well as the role of the CAR T-cell therapy in this disease or the main challenges AL amyloidosis is facing to improve treatment outcomes.